Skip to main content

GOG3005-ABB VIE Protocol M13-694: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Gynecologic Oncology Group

Start Date

November 1, 2015

End Date

January 31, 2022
 

Administered By

Duke Cancer Institute

Awarded By

Gynecologic Oncology Group

Start Date

November 1, 2015

End Date

January 31, 2022